{
    "name": "eltrombopag",
    "comment": "Rx",
    "other_names": [
        "Promacta"
    ],
    "classes": [
        "Hematopoietic Growth Factors"
    ],
    "source": "https://reference.medscape.com/drug/promacta-eltrombopag-342178",
    "pregnancy": {
        "common": [
            "Available data from published case reports and postmarketing experience with use in pregnant women are insufficient to assess any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction and developmental toxicity studies, oral administration of eltrombopag to pregnant rats during organogenesis resulted in embryolethality and reduced fetal weights at maternally toxic doses",
                    "Effects were observed at doses resulting in exposures that were 6 times the human clinical exposure based on AUC in patients with chronic ITP at 75 mg/day, and 3 times the AUC in patients with chronic hepatitis C at 100 mg/day"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Based on animal reproduction studies, fetal harm may occur when administered to a pregnant woman",
                    "Use effective contraception in sexually-active females of reproductive during treatment and for at least 7 days after stopping treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data available regarding presence of eltrombopag or metabolites in human milk, effects on breastfed child, or on milk production",
            "However, drug was detected in pups of lactating rats 10 days postpartum suggesting potential for transfer during lactation; due to potential for serious adverse reactions in a breastfed child from drug, breastfeeding is not recommended during treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Risk for hepatic decompensation in chronic hepatitis C patients",
                    "description": [
                        "Risk of hepatotoxicity",
                        "In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase risk of hepatic decompensation",
                        "May increase risk of severe and potentially life-threatening hepatotoxicity",
                        "Monitor hepatic function and discontinue dosing as recommended"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "If patient with hepatic impairment (Child-Pugh Class A, B, C) initiates therapy for first- line treatment of severe aplastic anemia, reduce initial dose",
                "In aplastic anemia, use lowest dose to achieve and maintain hematologic response; discontinue if no hematologic response observed after 16 weeks of therapy, excessive platelet count responses or liver test abnormalities",
                "Chronic hepatitis C with cirrhosis may increase risk of hepatic decompensation and death when treated with alfa interferons; no dosage adjustment is recommended in patients with chronic hepatitis C and hepatic impairment",
                "Not indicated for the treatment of patients with myelodysplastic syndromes (MDS); increased risk of death and progression of MDS to acute myeloid leukemia observed in a clinical trial showing an increased relative risk of progression to AML by 166%",
                "Thrombotic/thromboembolic complications reported; have included both venous and arterial events and were observed at low and at normal platelet counts.",
                "Portal vein thrombosis reported in patients with chronic liver disease receiving therapy",
                "Consider potential risk of thromboembolism when administering to patients with known risk factors for thromboembolism (eg, Factor V Leiden, ATIII deficiency, antiphospholipid syndrome, chronic liver disease).",
                "Risk of thrombocytopenia and hemorrhage after discontinuation",
                "Not for normalizing platelet counts as it may increase thrombotic/thromboembolic complications; for use only when degree of thrombocytopenia and clinical conditions increase risk for bleeding in patients with chronic immune idiopathic thrombocytopenia",
                "May develop or worsen cataracts; screen before administering and during treatment",
                "Discontinue if platelet count does not respond to a level to avoid clinically important bleeding after 4 weeks at maximum recommended dose",
                "In hepatitis C, use only when thrombocytopenia prevents initiation and maintenance of interferon-based therapy; discontinue if antiviral therapy discontinued"
            ],
            "specific": [
                {
                    "type": "Hepatotoxicity",
                    "description": [
                        "May increase risk of severe and potentially life-threatening hepatotoxicity (see Black Box Warnings); monitor liver function before and during therapy",
                        "Treatment of ITP, chronic hepatitis C-associated thrombocytopenia, and refractory severe aplastic anemia",
                        "Measure serum ALT, AST, and bilirubin prior to initiation of therapy, every 2 weeks during dose adjustment phase, and monthly following establishment of a stable dose. Drug inhibits UDP Â­glucuronosyltransferase (UGT)1A1 and organic anion-transporting polypeptide (OATP)1B1, which may lead to indirect hyperbilirubinemia; if bilirubin is elevated, perform fractionation; evaluate abnormal serum liver tests with repeat testing within 3 to 5 days",
                        "If abnormalities are confirmed, monitor serum liver tests weekly until resolved or stabilized; discontinue treatment if ALT levels increase to greater than or equal to 3 x ULN in patients with normal liver function or greater than or equal to 3 x baseline (or greater than 5 x ULN, whichever is the lower) in patients with pre-treatment elevations in transaminases and are: progressively increasing, or persistent for greater than or equal to 4 weeks, or accompanied by increased direct bilirubin, or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation",
                        "If potential benefit for reinitiating treatment is considered to outweigh risk for hepatotoxicity, then consider cautiously reintroducing therapy and measure serum liver tests weekly during dose adjustment phase; hepatotoxicity may reoccur if therapy is reinitiated; if liver test abnormalities persist, worsen, or recur, then permanently discontinue therapy",
                        "First-line treatment of severe aplastic anemia",
                        "Measure ALT, AST, and bilirubin prior to initiation of therapy, every other day while hospitalized for h-ATG therapy, and then every 2 weeks during treatment; during treatment, manage increases in ALT or AST levels as recommended"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Polyvalent cations",
                        "Eltrombopag chelates polyvalent cations (eg, iron, calcium, aluminum, magnesium, selenium, zinc) in foods, mineral supplements, and antacids",
                        "Administer at least 2 hr before or 4 hr after any medications or products containing polyvalent cations such as antacids, dairy products, and mineral supplements to avoid significant reduction in absorption",
                        "OATP1B1 or BCRP transporters",
                        "Use caution when coadministering with OATP1B1 substrates (eg, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or BCRP (eg, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan)",
                        "Monitor closely for signs/symptoms of excessive exposure to OATP1B1 or BCRP substrates and consider reducing the dose of these drugs, if appropriate"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "alpelisib",
            "description": {
                "common": "eltrombopag will increase the level or effect of alpelisib by  Other (see comment). Avoid or Use Alternate Drug. Coadministration of alpelisib (BCRP substrate) with a BCRP inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "eltrombopag increases toxicity of atorvastatin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "calcium acetate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "calcium chloride decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "calcium citrate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "calcium gluconate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbonyl iron",
            "description": {
                "common": "carbonyl iron decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "eltrombopag increases levels of eluxadoline by decreasing metabolism. Avoid or Use Alternate Drug. Decrease eluxadoline dose to 75 mg PO BID if coadministered with OATP1B1 inhibitors. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ferric maltol",
            "description": {
                "common": "ferric maltol decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ferrous fumarate",
            "description": {
                "common": "ferrous fumarate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ferrous gluconate",
            "description": {
                "common": "ferrous gluconate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ferrous sulfate",
            "description": {
                "common": "ferrous sulfate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "eltrombopag increases toxicity of fluvastatin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iron dextran complex",
            "description": {
                "common": "iron dextran complex decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iron sucrose",
            "description": {
                "common": "iron sucrose decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "magnesium chloride",
            "description": {
                "common": "magnesium chloride decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "magnesium citrate",
            "description": {
                "common": "magnesium citrate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "magnesium hydroxide",
            "description": {
                "common": "magnesium hydroxide decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "magnesium oxide",
            "description": {
                "common": "magnesium oxide decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "magnesium sulfate",
            "description": {
                "common": "magnesium sulfate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ozanimod",
            "description": {
                "common": "eltrombopag increases toxicity of ozanimod by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of ozanimod (a BCRP substrate) with BCRP inhibitors increases the exposure of the minor (RP101988, RP101075) and major active metabolites (CC112273, CC1084037) of ozanimod, which may increase the risk of ozanimod adverse reactions. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pitavastatin",
            "description": {
                "common": "eltrombopag increases toxicity of pitavastatin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "polysaccharide iron",
            "description": {
                "common": "polysaccharide iron decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pravastatin",
            "description": {
                "common": "eltrombopag increases toxicity of pravastatin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rimegepant",
            "description": {
                "common": "eltrombopag will increase the level or effect of rimegepant by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of rimegepant (a BCRP substrate) with inhibitors of BCRP."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "riociguat",
            "description": {
                "common": "eltrombopag will increase the level or effect of riociguat by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Coadministration of riociguat (P-gp substrate) with strong P-gp inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rose hips",
            "description": {
                "common": "rose hips decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rosuvastatin",
            "description": {
                "common": "eltrombopag increases toxicity of rosuvastatin by Other (see comment). Avoid or Use Alternate Drug. \nComment: OATP1B1 inhibitors may increase risk of myopathy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selenium",
            "description": {
                "common": "selenium decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "simvastatin",
            "description": {
                "common": "eltrombopag will increase the level or effect of simvastatin by  Other (see comment). Avoid or Use Alternate Drug. OATP1B1 inhibitors may increase risk of myopathy"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sodium bicarbonate",
            "description": {
                "common": "sodium bicarbonate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sodium citrate/citric acid",
            "description": {
                "common": "sodium citrate/citric acid decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "talazoparib",
            "description": {
                "common": "eltrombopag will increase the level or effect of talazoparib by  Other (see comment). Avoid or Use Alternate Drug. BCRP inhibitors may increase systemic exposure of talazoparib (a BCRP substrate). If coadministration cannot be avoided, monitor for potential adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetaminophen",
            "description": {
                "common": "eltrombopag increases levels of acetaminophen by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetaminophen IV",
            "description": {
                "common": "eltrombopag increases levels of acetaminophen IV by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetaminophen rectal",
            "description": {
                "common": "eltrombopag increases levels of acetaminophen rectal by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "artesunate",
            "description": {
                "common": "eltrombopag will increase the level or effect of artesunate by  decreasing metabolism. Use Caution/Monitor. Coadministration may increase active artesunate metabolite (DHA) by inhibiting UGT. Monitor for increased adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "eltrombopag increases levels of aspirin rectal by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "eltrombopag increases levels of aspirin/citric acid/sodium bicarbonate by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir increases levels of eltrombopag by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "eltrombopag increases levels of atorvastatin by decreasing metabolism. Use Caution/Monitor. OATP transporter protein inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "eltrombopag increases levels of belladonna and opium by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "berotralstat",
            "description": {
                "common": "eltrombopag increases levels of berotralstat by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Reduced dose of berotralstat (a BCRP substrate) to 110 mg/day when coadministered with BCRP inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "eltrombopag increases levels of buprenorphine buccal by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "eltrombopag increases levels of celecoxib by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "eltrombopag increases levels of choline magnesium trisalicylate by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cigarette smoking",
            "description": {
                "common": "cigarette smoking will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "ciprofloxacin will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferiprone",
            "description": {
                "common": "eltrombopag will increase the level or effect of deferiprone by  decreasing metabolism. Use Caution/Monitor. Coadministration with UGT1A6 inhibitors may increase serum concentration of deferiprone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "eltrombopag increases levels of diclofenac by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "eltrombopag increases levels of diflunisal by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duvelisib",
            "description": {
                "common": "eltrombopag will increase the level or effect of duvelisib by  Other (see comment). Use Caution/Monitor. Coadministration of duvelisib (a BCRP substrate) with a BCRP transport inhibitor may increase levels or effects of duvelisib."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "esomeprazole will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "ethinylestradiol will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "eltrombopag increases levels of etodolac by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "eltrombopag increases levels of fenoprofen by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "eltrombopag increases levels of flurbiprofen by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "eltrombopag increases levels of fluvastatin by decreasing metabolism. Use Caution/Monitor. OATP transporter protein inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "eltrombopag will increase the level or effect of glecaprevir/pibrentasvir by  decreasing metabolism. Use Caution/Monitor. Monitor for glecaprevir/pibrentasvir adverse effects if coadministered with drugs that are OATP1B1 and BCRP inhibitor"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "eltrombopag increases levels of hydromorphone by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "eltrombopag increases levels of ibuprofen by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "eltrombopag increases levels of ibuprofen IV by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "eltrombopag increases levels of indomethacin by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "eltrombopag increases levels of ketoprofen by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "eltrombopag increases levels of ketorolac by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "eltrombopag increases levels of ketorolac intranasal by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leflunomide",
            "description": {
                "common": "leflunomide will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "eltrombopag increases levels of letermovir by decreasing metabolism. Use Caution/Monitor. Coadminstration of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase letermovir plasma concentrations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levorphanol",
            "description": {
                "common": "eltrombopag increases levels of levorphanol by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium supplement",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of eltrombopag by  Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 4 hr after"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "eltrombopag increases levels of meclofenamate by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "eltrombopag increases levels of mefenamic acid by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "eltrombopag increases levels of meloxicam by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meperidine",
            "description": {
                "common": "eltrombopag increases levels of meperidine by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "eltrombopag increases levels of methadone by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methotrexate",
            "description": {
                "common": "eltrombopag increases levels of methotrexate by decreasing metabolism. Use Caution/Monitor. OATP transporter protein inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "mexiletine will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miconazole vaginal",
            "description": {
                "common": "miconazole vaginal will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "eltrombopag increases levels of morphine by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "eltrombopag increases levels of nabumetone by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "eltrombopag increases levels of naproxen by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "nateglinide will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "opium tincture",
            "description": {
                "common": "eltrombopag increases levels of opium tincture by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "eltrombopag increases levels of oxaprozin by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "eltrombopag increases levels of oxycodone by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "eltrombopag increases levels of oxymorphone by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2a",
            "description": {
                "common": "peginterferon alfa 2a will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "eltrombopag increases levels of piroxicam by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "eltrombopag increases levels of repaglinide by decreasing metabolism. Use Caution/Monitor. OATP transporter protein inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "eltrombopag will decrease the level or effect of sacubitril/valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "eltrombopag increases levels of salicylates (non-asa) by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "eltrombopag increases levels of salsalate by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selenium",
            "description": {
                "common": "selenium will decrease the level or effect of eltrombopag by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate eltrombopag administration from polyvalent cations by at least 2 h."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selexipag",
            "description": {
                "common": "eltrombopag will increase the level or effect of selexipag by  Other (see comment). Use Caution/Monitor. Selexipag is a ABCG2 (BCRP) substrate. Monitor selexipag for increased pharmacologic or adverse effects when coadministered with ABCG2 (BCRP) inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smoking",
            "description": {
                "common": "smoking will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil",
            "description": {
                "common": "eltrombopag increases levels of sufentanil by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "sulfamethoxazole will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "eltrombopag increases levels of sulfasalazine by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "eltrombopag increases levels of sulindac by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tapentadol",
            "description": {
                "common": "eltrombopag increases levels of tapentadol by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobacco use",
            "description": {
                "common": "tobacco use will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "eltrombopag increases levels of tolmetin by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topotecan",
            "description": {
                "common": "eltrombopag will increase the level or effect of topotecan by  Other (see comment). Use Caution/Monitor. Avoid coadministration. Topotecan is a substrate of the efflux transporter BCRP. Eltrombopag inhibits BCRP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "eltrombopag will decrease the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zileuton",
            "description": {
                "common": "zileuton will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zinc",
            "description": {
                "common": "zinc will decrease the level or effect of eltrombopag by  cation binding in GI tract. Modify Therapy/Monitor Closely. Administer eltrombopag at least 2 hr before or 4 hr after oral administration of any polyvalent cation containing product."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "33"
        },
        {
            "name": "Fatigue",
            "percent": "28"
        },
        {
            "name": "Cough",
            "percent": "23"
        },
        {
            "name": "Diarrhea",
            "percent": "21"
        },
        {
            "name": "Headache",
            "percent": "21"
        },
        {
            "name": "Pain in extremity",
            "percent": "19"
        },
        {
            "name": "Pyrexia",
            "percent": "14"
        },
        {
            "name": "Dizziness",
            "percent": "14"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "14"
        },
        {
            "name": "Abdominal pain",
            "percent": "12"
        },
        {
            "name": "Muscle spasms",
            "percent": "12"
        },
        {
            "name": "Transaminases increased",
            "percent": "12"
        },
        {
            "name": "Arthralgia",
            "percent": "12"
        },
        {
            "name": "Rhinorrhea",
            "percent": "12"
        },
        {
            "name": "Rash",
            "percent": "7"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "7"
        },
        {
            "name": "Cataract",
            "percent": "2"
        }
    ]
}